epocrates logo
epocrates logo
epocrates logo
  • 0

Interaction Check

epocrates logo

Sign in to access our clinical decision support tools

Sign in Create Account

Selected Drugs Clear All

  • remove Besremi (ropeginterferon alfa-2b-njft)
    ropeginterferon alfa-2b
  • remove Mounjaro
    tirzepatide
  • remove Septra
    sulfamethoxazole/ trimethoprim

multicheck MultiCheck Results - 3 Interactions

Smiley face Smiley face

Avoid/Use Alternative

Smiley face Smiley face Besremi (ropeginterferon alfa-2b-njft) (ropeginterferon alfa-2b) + Septra (sulfamethoxazole/ trimethoprim)

Avoid/Use Alternative


ropeginterferon alfa-2b + trimethoprim

use alternative or monitor CBC: combo may incr. risk of myelosuppression (additive effects)

Caution Advised

Smiley face Smiley face Mounjaro (tirzepatide) + Septra (sulfamethoxazole/ trimethoprim)

Caution Advised


tirzepatide + sulfamethoxazole

caution advised w/ oral sulfamethoxazole: combo may decr. sulfamethoxazole levels, efficacy (absorption delayed, possibly decreased)

tirzepatide + trimethoprim

caution advised w/ oral trimethoprim: combo may decr. trimethoprim levels, efficacy (absorption delayed, possibly decreased)

Additional Considerations

Smiley face Smiley face ropeginterferon alfa-2b in Besremi (ropeginterferon alfa-2b-njft)

caution advised with narrow therapeutic index drugs; interferons may suppress CYP450 enzyme activity, resulting in incr. exposure of CYP substrates

Smiley face Smiley face tirzepatide in Mounjaro

caution advised with oral drugs, especially narrow therapeutic index; tirzepatide delays gastric emptying, may alter absorption of concomitant oral drugs

Help
FDA Reporting Form
 
Download Epocrates from the App Store Download Epocrates from the Play Store
About Us Features Business Solutions Help & Feedback
© 2026 epocrates, Inc.    Terms of Use Privacy Policy Editorial Policy Do Not Sell or Share My Information